BRD2 and prostate cancer: In this cell line, dual treatment with 2-DG and metformin produced significantly greater radiosensitisation than either agent administered alone, supporting our findings in UVW/NAT cells and consistent with data derived from breast cancer [48, 50], prostate cancer [47] and paediatric glioma cells [49].